At Anaxomics, we would like to engage in further conversation with our clients, our readers, and the users of our web platform, SIMScells. In this post we give you the insight into our technology TPMS.
The Anaxomics team published an article on the application of systems biology to the selection of nutraceutical treatments for NAFLD in the NUTRAfoods journal. This article describes the use of our proprietary TPMS technology to identify the best nutraceuticals for the treatment of NAFLD and to describe their action on the disease. You can read the […]
The transition from preclinical to clinical research marks a critical turning point in the drug development process. Unfortunately, despite high R&D expenditures, attrition rates remain high, with most drugs failing due to safety and efficacy issues. Discover the underlying causes of this long-standing problem and how systems biology can address it.
Are you involved in early drug development and need to compare the efficacy of your compound with other drug competitors? Do you want to test your hypotheses in human-physiology based models? Discover the Anaxomics customized in silico services for highlighting strengths of early-stage developmental compounds.
Anaxomics's systems biology-based drug repositioning combines the best from the heuristic and rational drug repositioning approaches, while overcoming their limitations. We offer both companies and academic and clinic researchers this 75 % success rate technology, which has let us patent several drugs and drug combinations.
Drugs act by affecting the function of different molecules of the human's body, or its invading pathogens in case of infectious diseases. The pathway leading from the molecules with which a drug directly interacts (its 'targets') to the ones that cause its effects is named its 'mechanism of action' or 'MoA'. Read this to learn how we help you to translate you clinical, preclinical or high-throughput data into the discovery of your drug's MoA.
Multidisciplinary approach to evaluate Diabetes as Alzheimer accelerator.
Bioinformatics’ applications to nutritional research and their impact on microbiota.
Anaxomics is a bioinformatics company molecularly modelling human physiology through Systems Biology and Artificial Intelligence. Our mathematical models of patients (either real or objective of study) allow the integration of experimental data (e.g. Big Data, omics data) with a proprietary translational database of clinical effectors, and offers virtual experimentation yielding faster, more economic, more insightful results.